Research Article

Safety and Pharmacokinetics of Motesanib in Combination with Panitumumab and Gemcitabine-Cisplatin in Patients with Advanced Cancer

Howard Burris,1 Joe Stephenson,2 Gregory A. Otterson,3 Mark Stein,4 Jesse McGreivy,5 Yu-Nien Sun,5 Megan Ingram,6 Yining Ye,6 and Lee S. Schwartzberg7

1 Sarah Cannon Research Institute, Nashville, TN 37203, USA
2 Cancer Center of the Carolinas, Greenville, SC 29605, USA
3 The Ohio State University, Columbus, OH 43210, USA
4 Robert Wood Johnson University Hospital, UMDNJ, New Brunswick, NJ 08903, USA
5 Amgen Inc., Thousand Oaks, CA 91320, USA
6 Amgen Inc., South San Francisco, CA 94080, USA
7 The West Clinic, Memphis, TN 38120, USA

Correspondence should be addressed to Howard Burris, howard.burris@scresearch.net

Received 29 July 2010; Accepted 12 February 2011

Academic Editor: David Ball

Copyright © 2011 Howard Burris et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. The aim of this study was to assess the safety and tolerability of motesanib (an orally administered small-molecule antagonist of vascular endothelial growth factor receptors 1, 2, and 3, platelet-derived growth factor receptor, and Kit) when administered in combination with panitumumab, gemcitabine, and cisplatin. Methods. This was an open-label, multicenter phase 1b study in patients with advanced solid tumors with an ECOG performance status ≤1 and for whom a gemcitabine/cisplatin regimen was indicated. Patients received motesanib (0 mg [control], 50 mg once daily [QD], 75 mg QD, 100 mg QD, 125 mg QD, or 75 mg twice daily [BID]) with panitumumab (9 mg/kg), gemcitabine (1250 mg/m2) and cisplatin (75 mg/m2) in 21-day cycles. The primary endpoint was the incidence of dose-limiting toxicities (DLTs). Results. Forty-one patients were enrolled and received treatment (including 8 control patients). One of eight patients in the 50 mg QD cohort and 5/11 patients in the 125 mg QD cohort experienced DLTs. The maximum tolerated dose was established as 100 mg QD. Among patients who received motesanib (n = 33), 29 had motesanib-related adverse events. Fourteen patients had serious motesanib-related events. Ten patients had motesanib-related venous thromboembolic events and three had motesanib-related arterial thromboembolic events, two of which were considered serious. One patient had a complete response and nine had partial responses as their best objective response. Conclusions. The combination of motesanib, panitumumab, and gemcitabine/cisplatin could not be administered consistently and, at the described doses and schedule, may be intolerable. However, encouraging antitumor activity was noted in some cases.

1. Introduction

Agents that inhibit angiogenesis, the process by which new blood vessels develop, have emerged as a viable treatment option for patients with solid tumors [1, 2]. In clinical studies, the most effective antiangiogenic agents tested thus far are those targeting either vascular endothelial growth factor (VEGF), which plays a crucial, rate-limiting role in angiogenesis [3], or its receptors VEGFR1 and VEGFR2 [1, 4–6]. Two other receptor tyrosine kinases, platelet-derived growth factor receptor (PDGFR) and stem cell factor receptor (Kit), have also been implicated in the pathogenesis of a variety of tumor types [7, 8]. Agents inhibiting these receptors have been shown to have antitumor efficacy [9, 10].

Recent studies suggest that treatment with a VEGF inhibitor in combination with cytotoxic chemotherapy and/or other targeted anticancer therapies may result in increased activity against solid tumors compared with monotherapy while maintaining an acceptable tolerability profile. Combining the monoclonal anti-VEGF antibody bevacizumab with carboplatin/paclitaxel resulted in longer survival time compared with chemotherapy treatment alone
Eligible patients were ≥18 years of age, had advanced cancer for which a gemcitabine/cisplatin regimen was clinically indicated, had an Eastern Cooperative Oncology Group performance status of 0 or 1, and had adequate cardiac, renal, and hepatic function. Patients with a history of another primary cancer were eligible if the cancer had been curatively treated with no known active disease or treatment in the 3 years before study enrollment. Key exclusion criteria were central nervous system metastases; history of arterial or venous thrombosis, pulmonary hemorrhage, or gross hemoptysis; uncontrolled hypertension (average systolic blood pressure >145 mm Hg or average diastolic blood pressure >85 mm Hg); myocardial infarction, cerebrovascular accident, transient ischemic attack, coronary angioplasty/stent, or unstable angina within 1 year of study enrollment; prior treatment with oral inhibitors of VEGF or anti-EGFR monoclonal antibodies; systemic chemotherapy within 28 days or radiation therapy for peripheral lesions within 14 days of enrollment; concurrent treatment with potent cytochrome P 450 3A inhibitors; absolute neutrophil count <1.5 × 10^9/L; platelet count <100 × 10^9/L; hemoglobin <9 g/dL; aspartate aminotransferase (AST) >2.5 × the upper limit of normal (ULN); alanine aminotransferase (ALT) >2.5 × ULN; alkaline phosphatase >2.0 × ULN. All patients provided written informed consent.

2. Methods

2.1. Patients. Eligible patients were ≥18 years of age, had advanced cancer for which a gemcitabine/cisplatin regimen was clinically indicated, had an Eastern Cooperative Oncology Group performance status of 0 or 1, and had adequate cardiac, renal, and hepatic function. Patients with a history of another primary cancer were eligible if the cancer had been curatively treated with no known active disease or treatment in the 3 years before study enrollment. Key exclusion criteria were central nervous system metastases; history of arterial or venous thrombosis, pulmonary hemorrhage, or gross hemoptysis; uncontrolled hypertension (average systolic blood pressure >145 mm Hg or average diastolic blood pressure >85 mm Hg); myocardial infarction, cerebrovascular accident, transient ischemic attack, coronary angioplasty/stent, or unstable angina within 1 year of study enrollment; prior treatment with oral inhibitors of VEGF or anti-EGFR monoclonal antibodies; systemic chemotherapy within 28 days or radiation therapy for peripheral lesions within 14 days of enrollment; concurrent treatment with potent cytochrome P 450 3A inhibitors; absolute neutrophil count <1.5 × 10^9/L; platelet count <100 × 10^9/L; hemoglobin <9 g/dL; aspartate aminotransferase (AST) >2.5 × the upper limit of normal (ULN); alanine aminotransferase (ALT) >2.5 × ULN; alkaline phosphatase >2.0 × ULN. All patients provided written informed consent.

2.2. Study Design. This was a two-part open-label, phase 1b, multicenter, sequential dose escalation study of motesanib plus panitumumab (Amgen Inc., Thousand Oaks, Calif, USA) and gemcitabine/cisplatin in patients with advanced solid tumors. Part 1 assessed the safety and tolerability of motesanib when administered in combination with panitumumab and gemcitabine/cisplatin; Part 2 was treated with motesanib at the MTD established in Part 1 (Figure 1). Eligibility criteria for Parts 1 and 2 were the same. The primary endpoint of Part 1 was the incidence of dose-limiting toxicities (DLT) as described below. Secondary endpoints included the incidence of adverse events and clinical laboratory abnormalities; the pharmacokinetics of motesanib when administered in combination with panitumumab and gemcitabine/cisplatin; and efficacy as assessed by modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria [20]. The primary endpoint of Part 2 was the response rate at the MTD established in Part 1. All study procedures were approved by each study center’s independent ethics committee or Institutional Review Board and were consistent with the Declaration of Helsinki.

2.3. Dose Escalation and Treatment. All patients received panitumumab and gemcitabine/cisplatin as described below. Motesanib was orally administered once daily (QD) or twice daily (BID) beginning on day 1 of treatment cycle 1 first thing in the morning on an empty stomach; patients were to refrain from eating for an hour after taking motesanib. Based on the tolerable doses established in a previous motesanib...
monotherapy study [14], patients in Part 1 of the study were enrolled in sequential cohorts of at least four to six patients each, receiving doses of 0 mg, 50 mg QD, 75 mg QD, 100 mg QD, 125 mg QD, or 75 mg BID (Figure 1). If one of the initial four enrolled patients experienced a DLT, two additional patients were enrolled in that cohort. The dose cohorts could be expanded, if necessary, to acquire additional safety or pharmacokinetic data or if the MTD was not established from the initial number of patients enrolled. Enrollment in the next cohort opened if the initial four enrolled patients completed the first treatment cycle without experiencing a DLT or if fewer than two of the initial six patients experienced a DLT.

Patients received 9 mg/kg panitumumab by intravenous infusion on day 1 of each cycle. Panitumumab was administered until intolerability or disease progression developed. Gemcitabine was administered on day 1 and day 8 (±1 day) of each cycle at a dose of 1250 mg/m². Cisplatin was administered on day 1 of each cycle at a dose of 75 mg/m². All treatment cycles were 21 days long, and additional time was allowed to recover from toxicity if necessary. Administration of panitumumab, motesanib, gemcitabine, and cisplatin continued until disease progression or unacceptable toxicity precluded further treatment.

Doses of motesanib, panitumumab, gemcitabine, and cisplatin could be withheld, modified, or delayed per study protocol-specified rules based on the occurrence of toxicities.

2.4. Dose-Limiting Toxicities and Maximum Tolerated Dose. Dose-limiting toxicity was defined as grade 3 fatigue persisting for ≥7 days or grade 4 fatigue; grade 3 or 4 nausea, diarrhea, or vomiting despite maximum supportive care; symptomatic pulmonary embolism (incidental asymptomatic pulmonary embolism or deep vein thrombosis identified during routine tumor imaging procedures was not DLTs); grade 3 or 4 neutropenia with fever >38.5°C; grade 4 neutropenia (absolute neutrophil count <0.5 × 10⁹/L) or thrombocytopenia (platelet count <25 × 10⁹/L) for >7 days; grade 4 hypertension; grade 4 rash/desquamation; grade 4 hypertension; AST or ALT >10 × ULN; symptomatic hypomagnesemia despite intravenous magnesium replacement; any other motesanib- and/or panitumumab-related grade 4 hematologic or grade 3 nonhematologic toxicity that was unacceptable in duration during the DLT period (cycle 1). The MTD was defined as the highest well-tolerated dose of motesanib when coadministered with panitumumab and gemcitabine/cisplatin.

2.5. Safety. Adverse events were recorded throughout the study and graded (including DLTs) according to the Common Terminology Criteria for Adverse Events, version 3.0. Samples for assessment of hematology, blood chemistry, urinalysis, and thyroid function were collected on day 1 of each cycle.

2.6. Pharmacokinetic Analyses. Plasma samples for intensive pharmacokinetic analysis of motesanib were collected before dose, at 1, 3, 6, and 12 hours (BID cohorts only), and at 24 hours after dose on day 1 of cycle 1. In addition, predose plasma samples for motesanib were collected on day 1 of cycles 2 and 3. Serum samples for analysis of panitumumab concentration were collected before dose and 30 minutes after the completion of infusion on day 1 of cycles 1, 2, and 4. Plasma samples for analysis of gemcitabine/cisplatin were collected at the completion of gemcitabine infusion on days 1 and 8 of cycles 1 and 2 and at the completion of cisplatin infusion on day 1 of cycles 1 and 2.

Plasma motesanib and gemcitabine concentrations were analyzed using a validated liquid chromatography/tandem mass spectrometry (LC-MS/MS) method, respectively. Serum panitumumab concentrations were assessed by an enzyme-linked immunosorbent assay. Total and free platinum (administered as cisplatin) were measured by validated, inductively coupled plasma mass spectrometry (MDS Pharma Services, Lincoln, Neb, USA). All pharmacokinetic parameter estimates were calculated using standard noncompartmental methods and WinNonlin Professional software on Citrix (Version 5.1.1, Pharsight Corporation, Mountain View, Calif, USA).

2.7. Efficacy Analysis. Magnetic resonance imaging or computed tomographic scans were performed at baseline and every 6 to 9 weeks throughout the study. Any finding of complete or partial response was confirmed between 4 and 6 weeks after the initial determination of complete or partial response. Target lesions were evaluated by the investigator using modified RECIST [20].

2.8. Statistical Analysis. All patients who received at least one dose of motesanib, panitumumab, or gemcitabine/cisplatin were included in the safety and efficacy analysis set. The pharmacokinetic analysis set included patients with evaluable pharmacokinetic samples.

3. Results

3.1. Patients. A total of 41 patients were enrolled in the study and received treatment with motesanib (except those in the 0-mg QD cohort; n = 8), panitumumab, and gemcitabine/cisplatin. Demographic and baseline characteristics are summarized in Table 1. The most common tumor type was NSCLC (51%), followed by pancreatic (12%). Almost all patients had stage IV disease (35, 85%), five patients had stage III disease, and one patient had stage II disease. Seventy-six percent of patients had not received prior chemotherapy, and 63% had not received prior radiation therapy. The median number of days on which motesanib was administered was 87 (range: 2–453). Patients received a median of six panitumumab infusions (range: 1–20), 10 gemcitabine infusions (range: 1–44), and five cisplatin infusions (range: 1–11). Median follow-up time (from the date of enrollment to the last on-study or long-term follow-up visit) was 24 weeks (range: 3–73). The first patient was enrolled in December 2004 and the last patient completed follow-up in May 2007. All patients discontinued treatment with motesanib and panitumumab; the most common
Table 1: Demographic and baseline clinical characteristics of study patients.

| Motesanib dose cohort | 0 mg QD (n = 8) | 50 mg QD (n = 8) | 75 mg QD (n = 6) | 100 mg QD (n = 6) | 125 mg QD (n = 11) | 75 mg BID (n = 2) |
|-----------------------|----------------|----------------|-----------------|-----------------|-----------------|-----------------|
| Female, n (%)         | 4 (50)         | 3 (38)         | 2 (33)          | 4 (67)          | 5 (45)          | 0 (0)           |
| Male, n (%)           | 4 (50)         | 5 (62)         | 4 (67)          | 2 (33)          | 6 (55)          | 2 (100)         |
| Race, n (%)           |                |                |                 |                 |                 |                 |
| White                 | 6 (75)         | 7 (88)         | 4 (67)          | 6 (100)         | 11 (100)        | 2 (100)         |
| Black                 | 1 (13)         | 1 (13)         | 2 (33)          | 0 (0)           | 0 (0)           | 0 (0)           |
| Hispanic or Latino    | 1 (13)         | 0 (0)          | 0 (0)           | 0 (0)           | 0 (0)           | 0 (0)           |
| Median age, y (range) | 52 (40–72)     | 65.5 (32–73)   | 57 (36–73)      | 52.5 (36–72)    | 63 (42–70)      | 65 (53–77)      |
| ECOG performance status, n (%) | | | | | | |
| 0                     | 6 (75)         | 3 (38)         | 1 (17)          | 5 (83)          | 6 (55)          | 1 (50)          |
| 1                     | 2 (25)         | 5 (63)         | 5 (83)          | 1 (17)          | 5 (45)          | 1 (50)          |
| Tumor type, n (%)     |                |                |                 |                 |                 |                 |
| Non–small-cell lung   | 3 (38)         | 5 (63)         | 3 (50)          | 4 (67)          | 4 (36)          | 2 (100)         |
| Pancreatic            | 3 (38)         | 0 (0)          | 0 (0)           | 0 (0)           | 2 (18)          | 0 (0)           |
| Esophageal            | 1 (13)         | 1 (13)         | 1 (17)          | 0 (0)           | 0 (0)           | 0 (0)           |
| Bladder               | 0 (0)          | 0 (0)          | 0 (0)           | 0 (0)           | 2 (18)          | 0 (0)           |
| Breast                | 0 (0)          | 0 (0)          | 0 (0)           | 2 (33)          | 0 (0)           | 0 (0)           |
| Kidney                | 0 (0)          | 0 (0)          | 0 (0)           | 0 (0)           | 1 (9)           | 0 (0)           |
| Ovarian               | 1 (13)         | 0 (0)          | 0 (0)           | 0 (0)           | 0 (0)           | 0 (0)           |
| Other                 | 0 (0)          | 1 (13)         | 0 (0)           | 0 (0)           | 2 (18)          | 0 (0)           |
| Unknown               | 0 (0)          | 1 (13)         | 2 (33)          | 0 (0)           | 0 (0)           | 0 (0)           |
| Number of sites of disease, n (%)<sup>a</sup> | | | | | | |
| 0                     | 1 (13)         | 1 (13)         | 1 (17)          | 0 (0)           | 1 (9)           | 0 (0)           |
| 1                     | 3 (38)         | 2 (25)         | 1 (17)          | 3 (50)          | 3 (27)          | 1 (50)          |
| 2                     | 4 (50)         | 5 (63)         | 3 (50)          | 2 (33)          | 5 (45)          | 1 (50)          |
| 3                     | 0 (0)          | 0 (0)          | 1 (17)          | 1 (17)          | 2 (18)          | 0 (0)           |
| Prior chemotherapy, n (%) | 6 (75)       | 4 (50)         | 5 (83)          | 4 (67)          | 10 (91)         | 2 (100)         |
| 1                     | 2 (25)         | 4 (50)         | 1 (17)          | 2 (33)          | 1 (9)           | 0 (0)           |
| Prior radiation therapy, n (%) | 6 (75)       | 3 (38)         | 4 (67)          | 4 (67)          | 8 (73)          | 1 (50)          |
| 1                     | 0 (0)          | 4 (50)         | 1 (17)          | 1 (17)          | 3 (27)          | 0 (0)           |
| 2                     | 2 (25)         | 1 (13)         | 1 (17)          | 1 (17)          | 0 (0)           | 1 (50)          |
| 3                     | 0 (0)          | 0 (0)          | 0 (0)           | 0 (0)           | 0 (0)           | 0 (0)           |

BID: twice daily; ECOG: Eastern Cooperative Oncology Group; QD: once daily.<sup>a</sup>As assessed by investigator.

reasons were adverse events (n = 13 and n = 11 patients, resp.) and disease progression (n = 8 and n = 10 patients, resp.).

3.2. Dose Escalation, Dose-Limiting Toxicities, and Maximum Tolerated Dose. Initially, four patients were enrolled in the 50-mg QD dose cohort. One patient had a DLT of grade 5 pulmonary embolism and died two days after the event. Subsequently, the cohort was expanded to six and later to eight patients in order to acquire additional safety data. No other DLTs occurred in this cohort. Six patients were then enrolled in the 75-mg QD cohort. No DLTs were observed. The next dose cohort (100 mg QD) again enrolled six patients. No DLTs occurred and dose escalation continued. Six patients were then initially enrolled in the 125-mg QD dose cohort. One patient had a DLT of grade 3 confusional state (lasting 4 days). In order to determine the motesanib MTD six additional patients were planned to be enrolled in this cohort. After five more patients had been added (to bring the total number of enrolled patients to 11), four experienced DLTs: grade 3 diarrhea, dehydration, and hypotension; grade 3 diarrhea, dehydration, and asthenia; grade 4 fatigue (lasting 4 days); sudden death (occurring on study day 17). Subsequently, the motesanib
125-mg QD dose in combination with panitumumab and gemcitabine/cisplatin was deemed not tolerable, and cohort enrollment was suspended before the sixth planned patient was enrolled. The 75-mg BID dose cohort was opened but enrolled only two patients. No DLTs occurred; however, the cohort was terminated early because an increased risk of cholecystitis at this dose had been observed in other motesanib studies [14, 16, 17]. No patient in the study described here developed cholecystitis at any tested dose level (see below). Based on the incidence of DLTs in the 125-mg QD cohort, the MTD for motesanib in combination with panitumumab and gemcitabine/cisplatin was established at 100 mg QD.

3.3. Adverse Events. Of the 33 patients who received motesanib, 29 (88%) experienced adverse events considered by the investigator to be related to motesanib treatment: most frequently hypertension (n = 15 patients), nausea (n = 15), fatigue (n = 14), diarrhea (n = 10), anorexia (n = 8), pulmonary embolism (n = 8), and vomiting (n = 8) (Table 2). A number of adverse events considered by the investigator to be related to motesanib treatment that were of specific interest occurred, including events that are considered class effects of VEGF(R) treatment [21], such as hypertension, thromboembolic events, hemorrhagic events, and neutropenia (Table 2). Cholecystitis and hypothyroidism, which have been described in other motesanib studies [14–17], did not occur. One patient in the 100 mg QD cohort had grade 3 cholelithiasis and one patient in the 125 mg QD cohort had grade 1 jaundice.

A total of 10 patients (24%) had venous thromboembolic events and three patients (7%) had arterial thromboembolic events (two of whom had arterial thrombi) related to motesanib treatment (Table 2). These adverse events occurred across all dose cohorts. Specifically, eight patients (20%) had grade 4 or 5 (one patient) pulmonary embolism, four patients (10%) had deep vein thrombosis (grade 2 or 3), and one patient (2%) had grade 2 jugular vein thrombosis. In most patients the venous thromboembolic events were manageable with anticoagulation therapy without the occurrence of a second thromboembolic event. Two patients with NSCLC had arterial thrombosis (grade 3 and 4, resp.) that were rated serious.

Fourteen patients (34%) had serious adverse events considered related to motesanib treatment, most of whom (n = 8) were enrolled in the 125-mg QD cohort: pulmonary embolism (n = 3); deep vein thrombosis, dehydration, and diarrhea (n = 2 each); arterial thrombosis, asthenia, atrial fibrillation, confusional state, headache, hypotension, and sudden death (n = 1 each). Six patients (15%) had at least one motesanib-related serious adverse event with a worst grade of 4. Five patients died on study. Two deaths (pulmonary embolism, 50 mg QD, and sudden death, 125 mg QD) occurred within 30 days of treatment and were considered by the investigator to be related to motesanib and panitumumab. The three other deaths were due to disease progression (n = 2) and hepatic failure and were considered unrelated to treatment.

Although Part 1 of the study (dose escalation) was successfully completed, Part 2 was not conducted due to the high incidence of thromboembolic adverse events observed in Part 1.

Forty patients (98%) experienced panitumumab-related adverse events, mostly erythema (n = 25 patients), dermatitis acneiform (n = 23), rash (n = 22), nausea (n = 21), fatigue, (n = 19), pruritus (n = 18), hypomagnesemia (n = 17), diarrhea (n = 16), vomiting (n = 12), anorexia (n = 11), anemia (n = 7), and dry skin (n = 7). Eleven patients (27%) had serious panitumumab-related events, most frequently deep vein thrombosis, dehydration, pulmonary embolism (3 patients, 7%, each) and diarrhea (2 patients, 5%). Deep vein thrombosis and pulmonary embolism were only observed in patients who also received motesanib. Among the 8 patients who did not receive motesanib (i.e., those who received panitumumab and gemcitabine/cisplatin only), the most frequently occurring panitumumab-related adverse events were rash (n = 6), nausea (n = 6), dermatitis acneiform (n = 5), erythema (n = 5), and pruritus (n = 5). Thromboembolic events, hemorrhagic events, dehydration, and hypertension did not occur in these patients.

Twenty patients (49%) had at least one motesanib dose interruption. In ten of these patients the interruptions were related to adverse events, and five of the ten patients had at least one dose reduction. Panitumumab dose delays and dose reductions occurred in 21 patients (51%) each. Fifteen and 20 patients had dose interruptions of gemcitabine and cisplatin, respectively.

3.4. Pharmacokinetics. Concentration-versus-time profiles and pharmacokinetic parameter estimates for motesanib are shown in Figure 2 and Table 3, respectively. Motesanib was rapidly absorbed following oral administration in combination with panitumumab and gemcitabine-cisplatin. Median time of maximum observed plasma concentration (t_max) was approximately 1 hour observed across all dose cohorts. Mean estimated terminal elimination half-life (t_1/2) was between 5.21 and 6.72 hours, and there was no apparent dose effect. The mean maximum observed plasma concentration (C_max) area under the plasma concentration-versus-time curve from time 0 to infinite time (AUC_0-inf), and observed concentration at 24 hours after dose (C_24) observed in patients in the 125-mg QD dose cohort were similar to those observed in a monotherapy study of motesanib [14]. However, for doses below 125 mg QD, mean C_max (but not AUC_0-inf or C_24) values were slightly lower compared with the monotherapy study [14]. Mean daily motesanib C_24 was above the IC_50 for human umbilical vein endothelial cell (HUVEC) proliferation (4 ng/mL) [13] in all dose cohorts and higher than the 90% inhibitory concentration (IC_90) for HUVEC proliferation (28 ng/mL) in the 125-mg QD and 75-mg BID dose cohorts.

The serum plasma concentrations of panitumumab, gemcitabine, and cisplatin are summarized in Table 4. Peak and trough serum concentrations of panitumumab were generally similar across all dose cohorts, although predose concentrations during cycle 4 were higher in the dose cohort without motesanib compared with all motesanib dose
Table 2: Patient incidence of motesanib-related adverse events.

| Motesanib dose cohort | 0 mg QD (n = 8) | 50 mg QD (n = 8) | 75 mg QD (n = 6) | 100 mg QD (n = 6) | 125 mg QD (n = 11) | 75 mg BID (n = 2) |
|-----------------------|----------------|----------------|----------------|----------------|----------------|----------------|
| **Patients with any related AE, n (%)** | 0 (0) | 6 (75) | 6 (100) | 4 (67) | 11 (100) | 2 (100) |
| Grade 3               | 0 (0) | 2 (25) | 2 (33) | 1 (17) | 6 (55) | 1 (50) |
| Grade 4               | 0 (0) | 0 (0) | 2 (33) | 2 (33) | 3 (27) | 1 (50) |
| Grade 5               | 0 (0) | 1 (13) | 0 (0) | 0 (0) | 1 (9) | 0 (0) |
| Related AEs occurring in ≥10% of all patients, n (%) | | | | | | |
| **Hypertension**      | 0 (0) | 3 (38) | 4 (67) | 2 (33) | 5 (45) | 1 (50) |
| **Nausea**            | 0 (0) | 4 (50) | 5 (83) | 2 (33) | 4 (36) | 0 (0) |
| **Fatigue**           | 0 (0) | 4 (50) | 2 (33) | 2 (33) | 6 (55) | 0 (0) |
| **Diarrhea**          | 0 (0) | 1 (13) | 1 (17) | 0 (0) | 7 (64) | 1 (50) |
| **Anorexia**          | 0 (0) | 2 (25) | 0 (0) | 2 (33) | 4 (36) | 0 (0) |
| **Pulmonary embolism**| 0 (0) | 1 (13) | 2 (33) | 2 (33) | 3 (27) | 0 (0) |
| **Vomiting**          | 0 (0) | 2 (25) | 3 (50) | 1 (17) | 2 (18) | 0 (0) |
| **Dermatitis acniform**| 0 (0) | 1 (13) | 2 (33) | 0 (0) | 2 (18) | 0 (0) |
| **Rash**              | 0 (0) | 0 (0) | 1 (17) | 0 (0) | 2 (18) | 2 (100) |
| **Constipation**      | 0 (0) | 0 (0) | 2 (33) | 0 (0) | 2 (18) | 0 (0) |
| **Deep vein thrombosis**| 0 (0) | 1 (13) | 0 (0) | 1 (17) | 2 (18) | 0 (0) |
| **Dehydration**       | 0 (0) | 0 (0) | 1 (17) | 0 (0) | 3 (27) | 0 (0) |
| **Erythema**          | 0 (0) | 1 (13) | 2 (33) | 1 (17) | 0 (0) | 0 (0) |

Patients with related AEs of specific interest (all grades), n (%)

| Veneous thromboembolic events | 0 (0) | 2 (25) | 3 (50) | 2 (33) | 3 (27) | 0 (0) |
| Pulmonary embolism            | | | | | | |
| Grade 4                       | 0 (0) | 0 (0) | 2 (33) | 2 (33) | 3 (27) | 0 (0) |
| Grade 5                       | 0 (0) | 1 (13) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Deep vein thrombosis          | | | | | | |
| Grade 2                       | 0 (0) | 1 (13) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Grade 3                       | 0 (0) | 0 (0) | 0 (0) | 1 (17) | 2 (18) | 0 (0) |
| Jugular vein thrombosis       | | | | | | |
| Grade 2                       | 0 (0) | 0 (0) | 1 (17) | 0 (0) | 0 (0) | 0 (0) |
| Arterial thromboembolic events | | | | | | |
| Arterial thrombosis           | | | | | | |
| Grade 3                       | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (9) | 1 (50) |
| Grade 4                       | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (50) |
| Cerebrovascular accident      | | | | | | |
| Grade 2                       | 0 (0) | 1 (13) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |

Other

| Hemorrhagic events| 0 (0) | 1 (13) | 0 (0) | 1 (17) | 3 (27) | 0 (0) |
| Gallbladder disorder    | 0 (0) | 0 (0) | 1 (17) | 0 (0) | 0 (0) | 0 (0) |
| Neutropenia             | 0 (0) | 1 (13) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |

**AE**: adverse event; **BID**: twice daily; **QD**: once daily.

*One patient had grade 4 pulmonary embolism and grade 3 deep vein thrombosis.

*Two patients had grade 4 pulmonary embolism and grade 3 deep vein thrombosis.

*Includes epistaxis, gingival bleeding, hematemesis, hematochezia, and increased tendency to bruise.
null
Table 4: Mean concentrations of gemcitabine, platinum, and panitumumab.

| Motesanib dose cohort      | No motesanib (0 mg QD) | 50 mg QD | 75 mg QD | 100 mg QD | 125 mg QD | 75 mg BID |
|---------------------------|------------------------|----------|----------|-----------|-----------|----------|
| Plasma gemcitabine        |                        |          |          |           |           |          |
| concentration (cycle 1)   | n                      | 8        | 8        | 6         | 6         | 11       |
| Mean, ng/mL (SD)          | 11000 (4220)           | 8450 (7310) | 14400 (6020) | 6160 (3690) | 16100 (6800) | 8290 (NR) |
| Plasma platinum           |                        |          |          |           |           |          |
| concentration (cycle 1)   | n                      | 8        | 8        | 6         | 6         | 11       |
| Mean total platinum, ng/mL (SD) | 3580 (273)           | 2960 (730) | 3630 (399) | 3330 (536) | 3560 (524) | 3920 (NR) |
| Mean free platinum, ng/mL (SD) | 2190 (283)           | 1420 (924) | 2250 (584) | 1550 (321) | 2140 (469) | 2650 (NR) |
| Serum panitumumab         |                        |          |          |           |           |          |
| concentration             | Cycle 1                |          |          |           |           |          |
| n                         | 8                      | 8        | 6         | 6         | 11       |
| Postdose mean concentration, µg/mL (SD) | 206 (76.4)           | 174 (24.9) | 158 (24.2) | 194 (27.1) | 203 (82.9) |
|                          | Cycle 2                |          |          |           |           |          |
| n                         | 6                      | 7        | 6         | 6         | 1        |
| Predose mean concentration, µg/mL (SD) | 11.2 (15.5)           | 9.0 (5.8) | 13.1 (13.5) | 18.9 (10.7) | 13.4 (14.2) |
|                          | n                      | 6        | 5        | 6         | 4         | 1        |
| Postdose mean concentration, µg/mL (SD) | 186 (62.9)           | 193 (37.5) | 194 (21.5) | 224 (51.8) | 213 (39.0) |
|                          | Cycle 4                |          |          |           |           |          |
| n                         | 3                      | 3        | 6         | 2         | 0        |
| Predose mean concentration, µg/mL (SD) | 56.5 (39.6)           | 10.5 (6.4) | 32.5 (21.3) | 41.6 (16.5) | 21.7 (22.0) |
|                          | n                      | 3        | 3        | 6         | 2         | 0        |
| Postdose mean concentration, µg/mL (SD) | 275 (118)           | 232 (52.8) | 218 (26.1) | 290 (NR)  | 170 (55.0) |

BID: twice daily; NR: not reported; QD: once daily.
aMean free platinum concentrations are based on an assessment of platinum concentrations in plasma ultrafiltrate.

Table 5: Best tumor response per modified RECIST as assessed by investigator.

| Motesanib dose cohort      | 0 mg QD (n = 8) | 50 mg QD (n = 8) | 75 mg QD (n = 6) | 100 mg QD (n = 6) | 125 mg QD (n = 11) | 75 mg BID (n = 2) |
|---------------------------|----------------|-----------------|------------------|--------------------|--------------------|------------------|
| Patients with measurable disease at baseline, n (%) | 7 (88) | 7 (88) | 5 (83) | 6 (100) | 11 (100) | 2 (100) |
| Response assessment, n (%) |                |                |                  |                    |                    |                  |
| Confirmed complete response | 0 (0) | 0 (0) | 0 (0) | 1 (17) | 0 (0) | 0 (0) |
| Confirmed partial response | 2 (25) | 0 (0) | 1 (17) | 3 (50) | 2 (18) | 1 (50) |
| Stable disease | 4 (50) | 5 (63) | 4 (67) | 2 (33) | 4 (36) | 1 (50) |
| Durable stable disease | 1 (13) | 0 (0) | 3 (50) | 1 (17) | 1 (9) | 0 (0) |
| Progressive disease | 1 (13) | 2 (25) | 0 (0) | 0 (0) | 1 (9) | 0 (0) |
| Unevaluable | 0 (0) | 0 (0) | 1 (17) | 0 (0) | 1 (9) | 0 (0) |
| Not done | 1 (13) | 1 (13) | 0 (0) | 0 (0) | 3 (27) | 0 (0) |
| Clinical benefit rate (CR + PR + durable SD) | 6 (75) | 5 (83) | 5 (83) | 6 (100) | 6 (55) | 2 (100) |
| Confirmed objective response, % (95% CI) | 25 (3.2–65.1) | 0 (0–36.9) | 17 (0.4–64.1) | 4 (22.3–95.7) | 18 (2.3–51.8) | 50 (1.3–98.7) |

BID: twice daily; QD: once daily; RECIST: Response Evaluation Criteria in Solid Tumors.
aPatients with a response assessment of complete response or partial response that was not confirmed within 4 weeks are reported as stable disease.
bDurable stable disease is defined as stable disease with a duration of ≥ 24 weeks.
cUn evaluable includes patients with a response assessment of complete response, partial response, or stable disease before the scheduled first assessment of response without an additional assessment of response.
dBinomial proportion with exact 95% confidence interval.
cohort experienced DLTs, and there was one sudden death among patients receiving this dose. The patient incidence of motesanib-related adverse events in general and, more specifically, events commonly associated with VEGF( receptors) inhibitor therapy, such as hypertension or bleeding events [5, 21, 25, 26], was comparable across dose cohorts and similar to what has been reported in other motesanib monotherapy and combination studies [14–16]. However, there was a high incidence of thromboembolic events for the treatment regimen as a whole. Specifically, 10 patients (24%) had venous thromboembolic events and three patients (7%) had arterial thromboembolic events (two of whom had arterial thrombi). The most frequently occurring thromboembolic events were grade 4 pulmonary embolism (n = 8), grade 3 deep vein thrombosis (n = 3), and grade 3/4 arterial thrombosis (n = 2). There was one grade 5 event of pulmonary embolism and one sudden death in the 125-mg QD cohort, both of which were considered by the investigator to be related to motesanib treatment. In comparison, in a phase 2 study of the anti-VEGF antibody bevacizumab plus carboplatin/paclitaxel in patients with locally advanced or metastatic NSCLC the patient incidence rate of thrombotic events was 17.6% in the 15-mg/kg cohort (grade 3/4, n = 5) [27]. The adverse event profile observed in the present study indicates that the combination treatment of motesanib, panitumumab, and gemcitabine/cisplatin at the doses and the schedule it was administered is not tolerable. Consequently, Part 2 of the study (which aimed to investigate efficacy at the MTD) was not enrolled.

The observation that this regimen is not tolerable is consistent with recently published studies reporting that combinations of VEGF inhibitors, EGFR inhibitors, and cytotoxic chemotherapy may be difficult to tolerate [28–30]. For example, in a study that investigated treatment with bevacizumab plus erlotinib, 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) in patients with metastatic colorectal cancer 27 of the 35 patients (77%) who were enrolled withdrew owing to protocol-defined toxicity or intolerable adverse effects, including grade 3 rash, hospitalization for febrile neutropenia, grade 3 nausea and emesis, and others [31]. Specifically, adverse events leading to study withdrawal included neurologic toxicity (six patients), small bowel obstruction (two patients), and other toxicity (nine patients). Similarly, two phase 3 studies that assessed the combination of chemotherapy, bevacizumab, and an anti-EGFR monoclonal antibody in patients with advanced metastatic colorectal cancer found that this combination did not improve outcomes but was associated with exacerbated toxicity compared with chemotherapy plus bevacizumab alone [28–30]. In contrast, treatments that combine only one targeted therapy and one cytotoxic chemotherapy appear to be better tolerated. For example, treatment with motesanib plus gemcitabine in patients with solid tumors showed acceptable toxicity [19], while treatment with panitumumab in combination with infusional 5-fluorouracil has been shown to be tolerable in patients with metastatic colorectal cancer [32]. The utility of anti-VEGF/anti-EGFR/chemotherapy combinations may be dependent upon both the setting and the combination of agents investigated. Indeed, given that administration of different agents targeting similar signaling pathways in combination with chemotherapy can result in dissimilar outcomes [33, 34], it is likely that only a specific anti-VEGF/anti-EGFR/chemotherapy combination will be effective against a particular tumor type. Consequently, it remains possible that anti-VEGF/anti-EGFR/chemotherapy combinations that have antitumor activity and acceptable toxicity may yet be identified. It should be noted that anti-VEGF/anti-EGFR/chemotherapy regimens are under further investigation in more highly selected patient populations such as those with NSCLC (SWOG-S0819 [NCT00946712]).

At present the mechanisms responsible for the increased incidence of adverse events associated with anti-VEGF/anti-EGFR/chemotherapy combinations are unknown. One plausible explanation is that pharmacodynamic interactions between the VEGF and EGF signaling pathways may result in excess toxicity [35].

In the present study, the incidence of panitumumab-related adverse events in the small group of patients who received panitumumab in combination with only gemcitabine/cisplatin (0-mg motesanib cohort) appeared to be similar to that observed in previous panitumumab monotherapy [36] and combination therapy studies [32, 37, 38]. The increased thrombogenicity may be related to the cytotoxic doublet (gemcitabine/cisplatin) as observed in other studies [39, 40].

There was no clear evidence of pharmacokinetic interactions between motesanib, panitumumab, gemcitabine, and cisplatin. Coadministration of panitumumab, gemcitabine, and cisplatin did not result in increased exposure to motesanib compared with monotherapy studies [14–16]. These results suggest that there was no apparent trend of pharmacokinetic interactions, given that motesanib is primarily metabolized by glucuronidation and cytochrome P 450 3A-mediated oxidation [41] and each of the other reagents is metabolized or eliminated by a different mechanism [42–44].

The objective response rate of 24% and median progression-free survival of 197 days observed in this study suggest that the regimen of motesanib, panitumumab, and gemcitabine/cisplatin may have some clinical benefit in some patients with advanced solid tumors. However, given the observed safety signals, the relatively small size of the study population, and the absence of a comparator group, it is difficult to interpret the data.

In conclusion, the MTD for motesanib in combination with panitumumab and gemcitabine/cisplatin was established at 100 mg QD. However, there was a strong safety signal of thromboembolic events for the treatment regimen as a whole. Overall, the combination could not be administered consistently and, at the described doses and schedule, may be intolerable to patients although encouraging antitumor activity was noted in some patients.

Acknowledgments
The authors would like to thank Rebeca Melara, M.S. (Amgen Inc.), for pharmacokinetic data analysis; Bernd Bruenner, Ph.D., and Cindy Wake, B.S. (Amgen Inc.), for
pharmacokinetic sample analysis; Ali Hassan, Ph.D. (Complete Healthcare Communications Inc.), whose work was funded by Amgen Inc., and Beate Quednau, Ph.D. (Amgen, Inc.), for assistance in the preparation of this paper.

References

[1] P. Carmeliet, “Angiogenesis in life, disease and medicine,” Nature, vol. 438, no. 7070, pp. 932–936, 2005.
[2] J. Folkman, “Role of angiogenesis in tumor growth and metastasis,” Seminars in oncology, vol. 29, no. 6, pp. 15–18, 2002.
[3] N. Ferrara, H. P. Gerber, and J. LeCouter, “The biology of VEGF and its receptors,” Nature Medicine, vol. 9, no. 6, pp. 669–676, 2003.
[4] G. K. Abou-Alfa, L. Schwartz, S. Ricci et al., “Phase II study of sorafenib in patients with advanced hepatocellular carcinoma,” Journal of Clinical Oncology, vol. 24, no. 26, pp. 4293–4300, 2006.
[5] R. J. Motzer, B. I. Rini, R. M. Bukowski et al., “Sunitinib in patients with metastatic renal cell carcinoma,” Journal of the American Medical Association, vol. 295, no. 21, pp. 2516–2524, 2006.
[6] A. Sandler, R. Gray, M. C. Perry et al., “Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer,” New England Journal of Medicine, vol. 355, no. 24, pp. 2542–2550, 2006.
[7] M. C. Heinrich, C. D. Blanke, B. J. Druker, and C. L. Corless, “Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies,” Journal of Clinical Oncology, vol. 20, no. 6, pp. 1692–1703, 2002.
[8] J. Yu, C. Ustach, and H. R. C. Kim, “Platelet-derived growth factor signaling and human cancer,” Journal of Biochemistry and Molecular Biology, vol. 36, no. 1, pp. 49–59, 2003.
[9] D. Demetri, A. T. van Oosterom, C. R. Garrett et al., “Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial,” The Lancet, vol. 368, no. 9544, pp. 1329–1338, 2006.
[10] J. Verweij, P. G. Casali, J. Zalcberg et al., “Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial,” The Lancet, vol. 364, no. 9440, pp. 1127–1134, 2004.
[11] R. Pirker, J. R. Pereira, A. Szczesna et al., “Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial,” The Lancet, vol. 373, no. 9674, pp. 1525–1531, 2009.
[12] R. S. Herbst, V. J. O’Neill, L. Fehrenbacher et al., “Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 25, no. 30, pp. 4743–4750, 2007.
[13] A. Polverino, A. Coxon, C. Starnes et al., “AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts,” Cancer Research, vol. 66, no. 17, pp. 8715–8721, 2006.
[14] L. S. Rosen, R. Kurzrock, M. Mulay et al., “Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors,” Journal of Clinical Oncology, vol. 25, no. 17, pp. 2369–2376, 2007.
[15] M. J. Schlumberger, R. Elisei, L. Bastholt et al., “Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer,” Journal of Clinical Oncology, vol. 27, no. 23, pp. 3794–3801, 2009.
[16] S. I. Sherman, L. J. Wirth, J. P. Droz et al., “Motesanib diphosphate in progressive differentiated thyroid cancer,” New England Journal of Medicine, vol. 359, no. 1, pp. 31–42, 2008.
[17] G. R. Blumenschein Jr., K. Reckamp, G. J. Stephenson et al., “Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer,” Clinical Cancer Research, vol. 16, no. 1, pp. 279–290, 2010.
[18] P. A. Kaufman, R. de Boer, S. White et al., “Phase 1b study of motesanib diphosphate (AMG 706) in combination with paclitaxel or docetaxel for the treatment of locally recurrent, unresetable or metastatic breast cancer,” in Proceedings of the San Antonio Breast Cancer Symposium, San Antonio, Tex, USA, December 2008, abstract 4117.
[19] T. J. Price, L. Lipton, J. McCreivy, S. McCoy, Y. N. Sun, and M. A. Rosenthal, “Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours,” British Journal of Cancer, vol. 99, no. 9, pp. 1387–1394, 2008.
[20] P. Therasse, S. G. Arbucket, E. A. Eisenhauer et al., “New guidelines to evaluate the response to treatment in solid tumors,” Journal of the National Cancer Institute, vol. 92, no. 3, pp. 205–216, 2000.
[21] F. A. L. M. Eskens and J. Verweij, “The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review,” European Journal of Cancer, vol. 42, no. 18, pp. 3127–3139, 2006.
[22] H. Hurwitz, L. Fehrenbacher, W. Novotny et al., “Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer,” New England Journal of Medicine, vol. 350, no. 23, pp. 2335–2342, 2004.
[23] J. Hainsworth and R. Herbst, “A phase III, multicenter, placebo-controlled, double-blind, randomized clinical trial to evaluate the efficacy of bevacizumab (Avastin) in combination with erlotinib (Tarceva) compared with erlotinib alone for treatment of advanced non-small cell lung cancer after failure of standard first-line chemotherapy (BETA),” Journal of Thoracic Oncology, vol. 3, pp. S302, 2008.
[24] V. A. Miller, P. O'Connor, C. Soh, F. Kabbinavar, and A. Investigators, “A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC),” Journal of Clinical Oncology, vol. 27, article LBA8002, 2009.
[25] H. S. Rugo, R. S. Herbst, G. Liu et al., “Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results,” Journal of Clinical Oncology, vol. 23, no. 24, pp. 5474–5483, 2005.
[26] A. L. Thomas, B. Morgan, M. A. Horsfield et al., “Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer,” Journal of Clinical Oncology, vol. 23, no. 18, pp. 4162–4171, 2005.
[27] D. H. Johnson, L. Fehrenbacher, W. F. Novotny et al., “Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 22, no. 11, pp. 2184–2191, 2004.

[28] J. R. Hecht, E. Mitchell, T. Chidiac et al., “A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 27, no. 5, pp. 672–680, 2009.

[29] J. Tol, M. Koopman, A. Cats et al., “Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer,” New England Journal of Medicine, vol. 360, no. 6, pp. 563–572, 2009.

[30] J. Tol, M. Koopman, C. J. Rodenburg et al., “A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity,” Annals of Oncology, vol. 19, no. 4, pp. 734–738, 2008.

[31] J. A. Meyerhardt, K. Stuart, C. S. Fuchs et al., “Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer,” Annals of Oncology, vol. 18, no. 7, pp. 1185–1189, 2007.

[32] J. Berlin, J. Posey, S. Tchekmedyian et al., “Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer,” Clinical Colorectal Cancer, vol. 6, no. 6, pp. 427–432, 2007.

[33] M. J. Moore, D. Goldstein, J. Hamm et al., “Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group,” Journal of Clinical Oncology, vol. 25, no. 15, pp. 1960–1966, 2007.

[34] P. A. Philip, J. Benedetti, C. L. Corless et al., “Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: southwest oncology group-directed intergroup trial S0205,” Journal of Clinical Oncology, vol. 28, no. 22, pp. 3605–3610, 2010.

[35] J. L. Marshall, “Vascular endothelial growth factor plus epidermal growth factor receptor dual targeted therapy in metastatic colorectal cancer: Synergy or antagonism?” Journal of Oncology, vol. 2009, Article ID 937305, 9 pages, 2009.

[36] E. Van Cutsem, S. Siena, Y. Humblet et al., “Phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): patient-reported outcomes (PRO),” in Proceedings of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Orlando, Fla, USA, January 2010.

[37] S. Siena, J. Cassidy, J. Tabernero et al., “Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared to FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): PRIME trial,” in Proceedings of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Orlando, Fla, USA, January 2010.

[38] R. Barcelò, A. Munoz, G. López-Vivanco, G. Numico, M. Merlano, and N. Silvestris, “Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine,” Cancer, vol. 104, no. 5, pp. 1110–1111, 2005.

[39] B. C. Kuenen, L. Rosen, E. F. Smit et al., “Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors,” Journal of Clinical Oncology, vol. 20, no. 6, pp. 1657–1667, 2002.

[40] C. Li, M. Kuchimanchi, D. Hickman et al., “In vitro metabolism of the novel, highly selective oral angiogenesis inhibitor motesanib diphosphate in preclinical species and in humans,” Drug Metabolism and Disposition, vol. 37, no. 7, pp. 1378–1394, 2009.

[41] A. Andersson, J. Fagerberg, R. Lewensohn, and H. Ehrsson, “Pharmacokinetics of cisplatin and its monohydrated complex in humans,” Journal of Pharmaceutical Sciences, vol. 85, no. 8, pp. 824–827, 1996.

[42] E. Mini, S. Nobili, B. Caciagli, I. Landini, and T. Mazzei, “Cellular pharmacology of gemcitabine,” Annals of Oncology, vol. 17, no. 5, pp. v7–v12, 2006.

[43] M. A. Tabrizi, C. M. L. Tseng, and L. K. Roskos, “Elimination mechanisms of therapeutic monoclonal antibodies,” Drug Discovery Today, vol. 11, no. 1-2, pp. 81–88, 2006.